Dosage Calculator
Determine the appropriate
dosage for your patient.
Look over the patient treatment profile, and get helpful information for starting RAVICTI.
For patients with urea cycle disorders (UCDs), controlling ammonia is a process that typically includes dietary modifications, supplements, and sometimes nitrogen scavenger therapies.b As an oral liquid treatment for patients with UCDs with no pills or powders to prepare, RAVICTI is made to fit today’s busy lives.1,2
bLIMITATIONS OF USE
RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels.
The safety and efficacy of RAVICTI for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established.
Instruct patients to use the RAVICTI bottle and oral syringe as follows1:
Determine the appropriate
dosage for your patient.
Determine your patient’s plasma
PAA:PAGN ratio and urinary PAGN level.
Horizon By Your Side (HBYS)
helps patients with payor
access to RAVICTI.
References: 1. RAVICTI (glycerol phenylbutyrate) Oral Liquid [prescribing information] Horizon. 2. Häberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.
RAVICTI (glycerol phenylbutyrate) Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).
The most common adverse reactions reported in clinical trials (at least 10% of patients) were:
Please see Full Prescribing Information.
RAVICTI (glycerol phenylbutyrate) Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).
The most common adverse reactions reported in clinical trials (at least 10% of patients) were:
Please see Full Prescribing Information.